Salix, Progenics announce FDA approval for Relistor

RALEIGH, N.C. and TARRYTOWN, N.Y. — Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain. The drug currently is the only available medication approved for treating opioid-induced constipation at the cause without interfering with the properties of the opioid, the companies said. 

 

“Frequently, opioid analgesics are prescribed to manage pain in patients suffering from chronic conditions. Unfortunately, the use of an opioid can result in debilitating constipation for a significant number of these patients,” said Bill Forbes, EVP, medical, research and development and chief development officer, Salix. “The approval and availability of Relistor for treating the underlying cause of OIC provides an important and welcomed advancement for many patients who experience constipation while taking opioids for chronic non-cancer pain.”